With the limited benefit of conventional chemotherapeutics and radiation and growing evidence of clinical activity of BRAF inhibitors in other cancer types such as melanoma, these agents have been also investigated for efficacy in thyroid cancer. The gene discussed is BRAF; the disease is melanoma.